Abstract: A corneal tissue exosome collected after rapid culture of a corneoscleral tissue directly following corneal transplantation is disclosed. The overall manufacturing process is simple, eliminating the procedures of thawing, isolation, and cell culture in conventional cell culture processes, and possesses high production yield and homogeneity, while reducing the generation of biomedical waste. The corneal tissue exosome obtained from the corneoscleral tissue exhibits specific protein expression and possesses potential for treating wound repair, ocular diseases, cancer, and immune-related diseases.

Abstract: The present disclosure provides a fusion protein including an anti-CD3 single domain antibody, an exosomal protein CD63 and an RNA binding protein. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Abstract: The present invention provides a central nervous system targeting pharmaceutical composition for treating various types of brain injuries. An integrin antibody is bound to a transmembrane protein of an exosome through genetic engineering, and the exosome is used as a carrier to encapsulate a therapeutic agent.

Abstract: A method for producing exosomes at a large scale is provided, in which a cyclic tensile bioreactor is used to stimulate exosome-producing cells to release exosomes. In addition, exosomes bearing an anti-HLA-G protein specific for binding HLA-G proteins expressed on cancer cells are provided for use as a drug carrier to deliver anti-cancer agents for treating cancer.

Abstract: A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

Abstract: An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of ?-syn in the striatum and delaying the course of Parkinson's disease.

Abstract: A medical data integration and analysis system includes a plurality of medical devices, a medical record database, a data flow processing device, a database managing device, an artificial intelligence predicting device and a vision displaying device. The medical devices respectively provide a plurality of detection data flows. The medical record database provides a record data flow for a plurality of patients. The data flow processing device is configured to assign the detection data flows and the record data flow. The database managing device for storing the detection data flows and the record data flow. The artificial intelligence predicting device provides a predicting data flow including the predicting results to the data flow processing device. The vision displaying device is for displaying the detected features, the patient features and the predicting results.

Abstract: The present disclosure provides a method for preventing formation of amyloid ? aggregation and a method for treating amyloidosis by using a synthetic peptide. The synthetic peptide of the present disclosure achieves the effect of preventing formation of amyloid ? aggregation and treating amyloidosis through various efficacy experiments.

Abstract: A method for producing exosomes in a large-scale by using a cyclic tensile bioreactor to stimulate cells to release exosomes. In addition, the exosome having an anti-HLA-G protein specific for cancer is used as a delivery vehicle to deliver therapeutic agents for treating cancer.

Abstract: A multispecific single domain antibodies chimeric antigen receptor and T-cell engager includes an HLA-G single domain antibody chimeric antigen receptor and a bispecific T-cell engager. The HLA-G single domain antibody chimeric antigen receptor includes an HLA-G single domain antibodies unit, a transmembrane domain, and a CD3z signaling domain. The bispecific T-cell engager includes a PD-L1 single domain antibodies unit and a CD3e single domain antibody.

Abstract: A method for assessing bacteremia includes the following steps. A blood analysis database is provided. A model establishing step is performed, wherein a plurality of reference cell population data, a plurality of reference complete blood counting data and a plurality of reference white blood cell differential counting data of the blood analysis database are trained to achieve a convergence by a machine learning algorithm model so as to obtain a bacteremia assessing classifier. A blood analysis data of a subject is provided, wherein the blood analysis data includes a cell population data, a complete blood counting data and a white blood cell differential counting data. An assessing step is performed, wherein the blood analysis data is analyzed by the bacteremia assessing classifier so as to obtain an assessing result of bacteremia of the subject.

Abstract: A method for improving drug loading efficiency into extracellular vesicles (10), involving the preparation of drug-loaded extracellular vesicles (10) by establishing an ammonium sulfate concentration gradient using a balanced crystalloid solution. This approach facilitates the efficient encapsulation of a target drug within extracellular vesicles (10) while maintaining stability in the balanced crystalloid environment.

Abstract: The present disclosure provides an anti-Staphylococcus aureus specific antibody and the nucleic acid encoding sequence thereof, and uses of the same. The anti-Staphylococcus aureus specific antibody of the present disclosure achieves the effect of treating Staphylococcus aureus infection and enhancing immune cells against Staphylococcus aureus through various efficacy experiments.

Abstract: An intelligent medical speech automatic recognition method includes performing a first model training step, a second model training step, a voice receiving step, a signal pre-treatment step and a transforming step. The first model training step is performed to train a generic statement data and a medical statement data of a database to establish a first model. The second model training step is performed to train a medical textbook data of the database to establish a second model. The voice receiving step is performed to receive a speech signal. The signal pre-treatment step is performed to receive the speech signal from the voice receiver and transform the speech signal into a to-be-recognized speech signal. The transforming step is performed to transform and recognize the to-be-recognized speech signal into a complete sentence writing character according to the first model and the second model.

Abstract: A drug carrier with a property of crossing the blood-brain barrier comprises an extracellular vesicle with a human leukocyte antigen-G antibody on its surface. This carrier can serve as a pharmaceutical composition for promoting apoptosis of brain tumor cells, inhibiting growth of brain tumor cells, or reducing expression of O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells. These effects contribute to the treatment of glioblastoma multiforme (GBM).

Abstract: The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Abstract: A cell repair-promoting extracellular vesicle, formed by silicate-induced stem cell secretion, helps express anti-inflammatory, tissue regeneration, and cell repair indicator factors, accelerating cell growth in wound tissue and the wound repair process.

Abstract: A BAG6 specific chimeric antigen receptor, a nucleic acid, a BAG6 specific chimeric antigen receptor expression plasmid, a BAG6 specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the BAG6 specific chimeric antigen receptor expressing cell are provided. The BAG6 specific chimeric antigen receptor specifically binds to BCL2 associated athanogene 6 (BAG6). The nucleic acid encodes the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expression plasmid expresses the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expressing cell is obtained by transducing the BAG6 specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: A method for assessing drug-resistant Stenotrophomonas maltophilia includes the following steps. A test sample is provided, wherein the test sample includes a Stenotrophomonas maltophilia. A spectrum analysis step is performed, wherein the test sample is detected by a mass spectrometry method so as to obtain a target mass spectrum data. An assessing step for drug-resistant Stenotrophomonas maltophilia is performed, wherein the target mass spectrum data is analyzed so as to assess whether the Stenotrophomonas maltophilia is susceptible or resistant to a ceftazidime antibiotic. When the Stenotrophomonas maltophilia is susceptible to the ceftazidime, the target mass spectrum data includes a first anti-ceftazidime feature mark, and a mass-to-charge ratio of the first anti-ceftazidime feature mark ranges from 5,965 to 5,975 daltons. When the Stenotrophomonas maltophilia is resistant to the ceftazidime, the target mass spectrum data is without a peak at the first anti-ceftazidime feature mark.

Abstract: A solution for preserving extracellular vesicles/exosomes has a carrier solvent selected from a group consisting of polysorbate 80, sucrose, and polyethylene glycol 3350/4000; and a stabilizer selected from a group consisting of salts, amino acids, and amino acid salts; wherein the pH of the preservation solution ranges from 5 to 7.4.